Chubb Limited · CB · FY2025 Q3 · Calendar Q4 2025
Chubb Q3 2025: Record Underwriting Profitability and Broad Growth
The supplied analysis supports a constructive but qualified view of Chubb's operating trajectory: strong underwriting, premium growth and investment income were paired with capital discipline and efficiency initiatives. The main offsets are catastrophe volatility, pricing pressure, casualty development and questions around ROE and excess capital.
Earnings scorecard
Reported versus consensusMarket reaction
event-close to next-session closeAsk FN2 about CB FY2025 Q3
Transcript, numbers and history already loadedFree account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Relative to the prior-quarter analysis, the supplied current analysis emphasizes record underwriting profitability, stronger investment income from private-equity and alternative allocations, continued international and consumer-line growth, and digital and AI initiatives. It also identifies catastrophe losses of $285 million and an 81.8% combined ratio as novel information.
Guidance delta
Maintained; the supplied analysis does not identify a change to guidance.
Key takeaways
- The supplied analysis describes record underwriting profitability, with core operating income up 29% and EPS up 31% year over year.
- Premium growth was led by consumer lines and international markets, particularly Asia and Latin America.
- Investment income benefited from higher-yielding private-equity and alternative allocations.
- Capital returns, digital initiatives and AI-supported efficiency remained management priorities.
Management priorities
- Maintain disciplined underwriting across all lines.
- Continue and increase share buybacks while building invested assets.
- Accelerate digital and AI initiatives to reduce expense growth.
- Grow international life and accident and health businesses, especially in Asia and Latin America.
Follow CB with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Analyst 52W Price Targets
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Sep 29, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Mizuho | Neutral | Neutral | Maintain | Sep 16, 2026 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | Aug 19, 2026 |
| Wells Fargo | Equal Weight | Equal Weight | Maintain | Jul 23, 2026 |
| Citizens | Market Outperform | Market Outperform | Maintain | Jul 22, 2026 |
| JP Morgan | Neutral | Neutral | Maintain | Jul 20, 2026 |
| Piper Sandler | Neutral | Neutral | Maintain | Jul 15, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | Jul 10, 2026 |
| Cantor Fitzgerald | Neutral | Neutral | Maintain | Jul 9, 2026 |
| UBS | Neutral | Neutral | Maintain | Jul 8, 2026 |
| Keefe, Bruyette & Woods | Outperform | Outperform | Maintain | Jul 8, 2026 |
| HSBC | Hold | Buy | Downgrade | Jul 6, 2026 |
| Barclays | Equal Weight | Equal Weight | Maintain | Jun 12, 2026 |
| B of A Securities | Underperform | Underperform | Maintain | Apr 14, 2026 |
| Deutsche Bank | Hold | Hold | Maintain | Mar 23, 2026 |
| BMO Capital | Market Perform | Market Perform | Maintain | Feb 10, 2026 |
| Raymond James | Strong Buy | Strong Buy | Maintain | Feb 9, 2026 |
| Citigroup | Buy | Buy | Maintain | Feb 9, 2026 |
| Roth Capital | Buy | Buy | Maintain | Feb 4, 2026 |
| Goldman Sachs | Buy | Neutral | Upgrade | Jan 8, 2026 |
| JMP Securities | Market Outperform | Market Outperform | Maintain | Oct 22, 2025 |
| Jefferies | Hold | Hold | Maintain | Apr 11, 2025 |
| RBC Capital | Outperform | Outperform | Maintain | Jan 30, 2025 |
| Roth MKM | Buy | Buy | Maintain | Jul 24, 2024 |
| William Blair | Underperform | Market Perform | Downgrade | Jun 28, 2024 |
| MKM Partners | Buy | Buy | Maintain | Dec 5, 2022 |
| Atlantic Equities | Overweight | Neutral | Upgrade | Nov 15, 2022 |
| Credit Suisse | Outperform | Outperform | Maintain | Nov 1, 2021 |
| Wolfe Research | Outperform | Outperform | Maintain | Aug 17, 2021 |
| Argus Research | Buy | Hold | Upgrade | Jul 30, 2021 |
| Compass Point | Neutral | Buy | Downgrade | May 29, 2019 |
| Sandler O'Neill | Hold | Buy | Downgrade | Apr 3, 2019 |
| Argus | Hold | Hold | Maintain | Apr 6, 2018 |
| PiperJaffray | Overweight | Overweight | Maintain | Oct 15, 2015 |
| Sterne Agee CRT | Buy | Buy | Maintain | Sep 21, 2015 |
| Bernstein | Outperform | Market Perform | Upgrade | Jul 31, 2015 |
| Janney Montgomery Scott | Buy | Neutral | Upgrade | Jul 24, 2015 |
| Janney Capital | Buy | Neutral | Upgrade | Jul 24, 2015 |
| Keefe Bruyette & Woods | Outperform | Market Perform | Upgrade | Jul 6, 2015 |
| Nomura | Neutral | Neutral | Maintain | Apr 25, 2014 |
| Evercore Partners | Equal Weight | Overweight | Downgrade | Dec 13, 2013 |
| Miller Tabak | Hold | Buy | Downgrade | Oct 3, 2013 |
| Guggenheim | Buy | Buy | Maintain | Sep 18, 2013 |
| Sterne Agee | Buy | Buy | Maintain | Jun 26, 2012 |
Named analyst price targets
Upside is calculated against the persisted current price $332.08. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Mizuho Securities | Yaron Kinar | $347 | $341.86 | +4.5% | Sep 16, 2026 |
| Morgan Stanley | Bob Huang | $360 | $345.29 | +8.4% | Aug 19, 2026 |
| Wells Fargo | Analyst unavailable | $356 | $343.23 | +7.2% | Jul 23, 2026 |
| Deutsche Bank | Cave Montazeri | $354 | $341.6 | +6.6% | Jul 22, 2026 |
| Atlantic Equities | Analyst unavailable | $301 | $339.6 | -9.4% | Jul 15, 2026 |
| Piper Sandler | Analyst unavailable | $374 | $346.22 | +12.6% | Jul 15, 2026 |
| Evercore ISI | Analyst unavailable | $374 | $345.34 | +12.6% | Jul 10, 2026 |
| Cantor Fitzgerald | Analyst unavailable | $337 | $355.09 | +1.5% | Jul 9, 2026 |
| Mizuho Securities | Analyst unavailable | $352 | $355.09 | +6.0% | Jul 9, 2026 |
| UBS | Brian Meredith | $369 | $356.49 | +11.1% | Jul 8, 2026 |
| Barclays | Analyst unavailable | $387 | $356.53 | +16.5% | Jul 7, 2026 |
| Morgan Stanley | Analyst unavailable | $340 | $361.17 | +2.4% | Jul 6, 2026 |
| HSBC | Vikram Gandhi | $373 | $361.17 | +12.3% | Jul 6, 2026 |
| Barclays | Analyst unavailable | $368 | $327.93 | +10.8% | Jun 12, 2026 |
| Wells Fargo | Elyse Greenspan | $333 | $325.43 | +0.3% | Apr 23, 2026 |
| BMO Capital | Michael Zaremski | $326 | $326.17 | -1.8% | Feb 10, 2026 |
| UBS | Analyst unavailable | $340 | $331.56 | +2.4% | Feb 9, 2026 |
| Seaport Global | Analyst unavailable | $373 | $330.7 | +12.3% | Feb 9, 2026 |
| Mizuho Securities | Analyst unavailable | $336 | $331.28 | +1.2% | Feb 6, 2026 |
| Goldman Sachs | Analyst unavailable | $366 | $331.28 | +10.2% | Feb 5, 2026 |
| Roth Capital | Analyst unavailable | $360 | $332.15 | +8.4% | Feb 4, 2026 |
| HSBC | Analyst unavailable | $354 | $299.96 | +6.6% | Jan 16, 2026 |
| Morgan Stanley | Analyst unavailable | $350 | $301.11 | +5.4% | Jan 16, 2026 |
| Mizuho Securities | Analyst unavailable | $317 | $300.69 | -4.5% | Jan 14, 2026 |
| Cantor Fitzgerald | Analyst unavailable | $309 | $300.69 | -7.0% | Jan 14, 2026 |
| Wells Fargo | Analyst unavailable | $305 | $306.62 | -8.2% | Jan 13, 2026 |
| Barclays | Analyst unavailable | $339 | $306.63 | +2.1% | Jan 8, 2026 |
| Goldman Sachs | Robert Cox | $351 | $306.63 | +5.7% | Jan 7, 2026 |
| Evercore ISI | David Motemaden | $346 | $307.52 | +4.2% | Jan 7, 2026 |
| Morgan Stanley | Bob Huang | $310 | $312.54 | -6.6% | Dec 16, 2025 |
| Mizuho Securities | Analyst unavailable | $318 | $312.54 | -4.2% | Dec 15, 2025 |
| Goldman Sachs | Alex Scott | $309 | $281.68 | -7.0% | Oct 27, 2025 |
| UBS | Analyst unavailable | $298 | $281.02 | -10.3% | Oct 27, 2025 |
| Cantor Fitzgerald | Analyst unavailable | $300 | $281.12 | -9.7% | Oct 27, 2025 |
| BMO Capital | Michael Zaremski | $283 | $281.16 | -14.8% | Oct 23, 2025 |
| Wells Fargo | Analyst unavailable | $293 | $276.52 | -11.8% | Oct 23, 2025 |
| Barclays | Analyst unavailable | $310 | $289.24 | -6.6% | Oct 8, 2025 |
| Evercore ISI | Analyst unavailable | $315 | $282.76 | -5.1% | Oct 1, 2025 |
| Wolfe Research | Tracy Benguigui | $320 | $274.33 | -3.6% | Sep 15, 2025 |
| Evercore ISI | David Motemaden | $312 | $270.15 | -6.0% | Jul 23, 2025 |
| Barclays | Alex Scott | $298 | $283.19 | -10.3% | Jul 7, 2025 |
| UBS | Brian Meredith | $304 | $282.18 | -8.5% | Apr 28, 2025 |
| Wells Fargo | Elyse Greenspan | $278 | $282 | -16.3% | Apr 24, 2025 |
| HSBC | Analyst unavailable | $323 | $287.01 | -2.7% | Mar 5, 2025 |
| Morgan Stanley | Michael Phillips | $300 | $283.76 | -9.7% | Oct 30, 2024 |
| Bank of America Securities | Joshua Shanker | $282 | $282.83 | -15.1% | Oct 10, 2024 |
| Bank of America Securities | Joshua Shanker | $275 | $288.54 | -17.2% | Oct 4, 2024 |
| Barclays | Alex Scott | $349 | $290.94 | +5.1% | Sep 4, 2024 |
| Bank of America Securities | Joshua Shanker | $264 | $263.25 | -20.5% | Jul 24, 2024 |
| Morgan Stanley | Bob Huang | $259 | $253.34 | -22.0% | Jul 10, 2024 |
| Evercore ISI | David Motemaden | $278 | $252.97 | -16.3% | May 16, 2024 |
| RBC Capital | Mark Dwelle | $285 | $243.01 | -14.2% | Apr 25, 2024 |
| HSBC | Vikram Gandhi | $270 | $254.79 | -18.7% | Apr 4, 2024 |
| Citigroup | Analyst unavailable | $229 | $216.25 | -31.0% | Feb 8, 2023 |
| Jefferies | Analyst unavailable | $246 | $227.18 | -25.9% | Jan 9, 2023 |
| RBC Capital | Analyst unavailable | $250 | $219.96 | -24.7% | Dec 14, 2022 |
| MKM Partners | Analyst unavailable | $260 | $216.79 | -21.7% | Dec 5, 2022 |
| Morgan Stanley | Analyst unavailable | $220 | $211.85 | -33.8% | Nov 22, 2022 |
| Raymond James | Analyst unavailable | $260 | $184.79 | -21.7% | Jul 28, 2022 |
| Wells Fargo | Analyst unavailable | $250 | $187 | -24.7% | Jul 28, 2022 |
| Morgan Stanley | Michael Phillips | $216 | $207.31 | -35.0% | May 24, 2022 |
| Barclays | Tracy Benguigui | $249 | $204 | -25.0% | May 22, 2022 |
| Raymond James | Gregory Peters | $250 | $206.45 | -24.7% | May 1, 2022 |
| Barclays | Tracy Benguigui | $250 | $206.45 | -24.7% | Apr 30, 2022 |
| RBC Capital | Analyst unavailable | $243 | $210.62 | -26.8% | Apr 28, 2022 |
| Barclays | Tracy Benguigui | $244 | $210.52 | -26.5% | Apr 16, 2022 |
| RBC Capital | Mark Dwelle | $239 | $212.58 | -28.0% | Apr 7, 2022 |
| Goldman Sachs | Alex Scott | $237 | $206.74 | -28.6% | Feb 2, 2022 |
| Evercore ISI | David Motemaden | $233 | $207.53 | -29.8% | Feb 2, 2022 |
| Wells Fargo | Elyse Greenspan | $230 | $206.74 | -30.7% | Feb 2, 2022 |
| JMP Securities | Matthew Carletti | $225 | $195.52 | -32.2% | Jan 14, 2022 |
| Credit Suisse | Andrew Kligerman | $225 | $190.79 | -32.2% | Nov 1, 2021 |
| Bank of America Securities | Joshua Shanker | $156 | $176.91 | -53.0% | Oct 7, 2021 |
| Deutsche Bank | Phil Stefano | $170 | $162.59 | -48.8% | Jul 12, 2021 |
Track every rating change on CB the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationChubb Limited, headquartered in Zurich, Switzerland, is a global insurer and reinsurer, offering a broad spectrum of products across various markets. In North America, its Commercial Property & Casualty (P&C) division caters to businesses of all scales, from large corporations to small enterprises, providing a wide range of policies. These encompass commercial property, casualty, workers' compensation, package deals, risk management, financial lines, marine, construction, environmental, medical, cyber risk, surety, and excess casualty, alongside group accident and health insurance. The North America Personal P&C unit serves affluent individuals and high-net-worth families, delivering coverage for homeowners, automobiles (including collector vehicles), valuable possessions, personal and excess liability, travel, and recreational marine risks, complete with related services.…
Historical context
All CB earningsFinancial Services peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| PUK Prudential plc | FY2026 Q2 · Calendar Q3 2026 | -40.9% | -0.5% | Prudential sustains growth and capital returns focus in H1 2026 |
| CM Canadian Imperial Bank of Commerce | FY2026 Q3 · Calendar Q3 2026 | +8.9% | -2.8% | CIBC Q3: Broad growth, resilient credit and expanded AI rollout |
| TD The Toronto-Dominion Bank | FY2026 Q3 · Calendar Q3 2026 | +13.8% | +1.4% | TD emphasizes growth investments alongside disciplined capital management |
| RY Royal Bank of Canada | FY2026 Q3 · Calendar Q3 2026 | +6.2% | -1.3% | RBC reports record Q3 earnings while investing for growth |
| AFRM Affirm Holdings, Inc. | FY2026 Q4 · Calendar Q3 2026 | +1230.3% | +0.3% | Affirm's most profitable quarter shifts focus to product execution |
Latest beats and misses
Who reports nextBeat on EPS
- COSTFY2026 Q4 · September 24, 2026+3.2% EPS+2.9% move
- SNXFY2026 Q3 · September 24, 2026+20.9% EPS-9.9% move
- DRIFY2027 Q1 · September 24, 20260.0% EPS-3.0% move
- CTASFY2027 Q1 · September 23, 2026+3.0% EPS-3.4% move
- PAYXFY2027 Q1 · September 23, 2026+1.5% EPS-8.8% move
- GISFY2027 Q1 · September 23, 2026+4.6% EPS+1.0% move
Get the CB recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
- Polygon adjusted daily market bars · 2026-09-29T18:51:02.854504+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-09-29T18:51:02.850865+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-09-29. For educational purposes only; not investment advice.